Viridian Therapeutics (STU:1S1) Research & Development: €278.96 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:1S1 Viridian Therapeutics Inc STU:1S1
52 GF Score
Price €19.90
! 5 Warning Signs
View Full Analysis

What is Viridian Therapeutics Research & Development?

Viridian Therapeutics STU:1S1 -1.49% 52 Research & Development is €278.96 Mil as of Jun. 2026. GuruFocus rates STU:1S1 with a GF Score™ of 52/100. The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Viridian Therapeutics's Research & Development for the three months ended in Jun. 2026 was €62.13 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 was €278.96 Mil.

Viridian Therapeutics  (STU:1S1) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Viridian Therapeutics Research & Development Related Terms

Viridian Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Viridian Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viridian Therapeutics Research & Development Chart

Viridian Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 50.34 95.24 146.51 227.53 289.45

Viridian Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 75.11 73.49 76.18 67.15 62.13
STU:1S1
52GF Score
Viridian Therapeutics Inc STU:1S1
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viridian Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €278.96 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €278.96 Mil mean?
Viridian Therapeutics (STU:1S1) has a Research & Development of €278.96 Mil as of Jun. 2026. Research and development expense is the total cost for research and development activities. View historical data on Viridian Therapeutics and its competitors.
Is Viridian Therapeutics' Research & Development too high?
Viridian Therapeutics' current Research & Development is €278.96 Mil. Overall, Viridian Therapeutics has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Viridian Therapeutics' Research & Development compare to BHVN and AGIO?
Viridian Therapeutics' Research & Development of €278.96 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Viridian Therapeutics and its competitors. Viridian Therapeutics's current Research & Development is €278.96 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viridian Therapeutics stock overvalued right now?
Viridian Therapeutics (STU:1S1) has a current Research & Development of €278.96 Mil. The current Research & Development is €278.96 Mil. Viridian Therapeutics' overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Viridian Therapeutics (STU:1S1), the current Research & Development is €278.96 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Viridian Therapeutics Business Description

Other Exchanges VRDN:USA0K1R:UK
Address 221 Crescent Street, Suite 103A, Waltham, MA, USA, 02453
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
52GF Score

Get the complete analysis for STU:1S1

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€19.90
Price